AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7923514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 50% with 10-minute iontophoresis
Number of subjects: 20
Study 3281031 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy plus carmustine (BCNU)
Number of subjects: 626
Study 3281031 — intervention group
Group type: COMPARATOR
Intervention: 60 Gy alone
Number of subjects: 626
Study 3281031 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy plus BCNU
Number of subjects: 626
Study 3281031 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy plus 10‐Gy boost
Number of subjects: 626
Study 3281031 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy plus semustine plus dacarbazine
Number of subjects: 626
Study 29801741 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session group psychosocial intervention (ACHD-CARE)
Number of subjects: 42
Study 29801741 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 42
Study 28441896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (⩽80 mg/day) for 12 weeks
Number of subjects: 112
Study 26654798 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-training program to improve self-regulation abilities
Number of subjects: 226
Study 26654798 — intervention group
Group type: COMPARATOR
Intervention: placebo control group
Number of subjects: 226
Study 23849147 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive trial design
Number of subjects: 720
Study 23849147 — intervention group
Group type: COMPARATOR
Intervention: Trial without adaptive randomization
Number of subjects: 720
Study 20693276 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposmic/anosmic participants
Number of subjects: 63
Study 20693276 — intervention group
Group type: COMPARATOR
Intervention: Normosmic control participants
Number of subjects: 63
Study 19043911 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 32
Study 19043911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15725285 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent
Number of subjects: 15
Study 15725285 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfectant
Number of subjects: 15
Study 15725285 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfectant/Detergent
Number of subjects: 15
Study 15725285 — intervention group
Group type: COMPARATOR
Intervention: Control area
Number of subjects: 15
Study 12921248 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid approaches
Number of subjects: 0
Study 12921248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic therapies (chlorambucil, cyclophosphamide)
Number of subjects: 0
Study 12921248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study 12921248 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 12921248 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies
Number of subjects: 0
Study 10566321 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Term Dissection (ATD)
Number of subjects: 500
Study 10566321 — intervention group
Group type: COMPARATOR
Intervention: Human Term Dissection (HTD)
Number of subjects: 500
Study 10566321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 500
Study 8739489 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous SCMC‐Lys 2.7 g once daily
Number of subjects: 662
Study 8739489 — intervention group
Group type: COMPARATOR
Intervention: Intermittent SCMC‐Lys 2.7 g
Number of subjects: 662
Study 8739489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study 1721550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 12
Study 1721550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6797571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg by mouth twice daily
Number of subjects: 117
Study 6797571 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide 250 mg by mouth four times daily with hydrocortisone 20 mg twice daily
Number of subjects: 117
Study 6797571 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide after tamoxifen failure
Number of subjects: 117
Study 6797571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen after aminoglutethimide failure
Number of subjects: 117
Study 6797571 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of aminoglutethimide
Number of subjects: 117
Study 6797571 — intervention group
Group type: COMPARATOR
Intervention: Side effects of tamoxifen
Number of subjects: 117
Study 31000253 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing live fish consumption frequency
Number of subjects: 800
Study 31000253 — intervention group
Group type: EXPERIMENTAL
Intervention: Price importance
Number of subjects: 800
Study 31000253 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety satisfaction
Number of subjects: 800
Study 28424258 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin concentrations measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395
Study 28424258 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin as a diagnostic test for iron deficiency
Number of subjects: 395
Study 28424258 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395
Study 28424258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395
Study 28424258 — intervention group
Group type: EXPERIMENTAL
Intervention: sTfR levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395
Study 28424258 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels measured at 14, 20, and 30 weeks of gestation
Number of subjects: 395
Study 25876654 — intervention group
Group type: EXPERIMENTAL
Intervention: Duty cycle 0.6
Number of subjects: 9
Study 25876654 — intervention group
Group type: COMPARATOR
Intervention: Duty cycle 0.3
Number of subjects: 9
Study 24229349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 224
Study 24229349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts (in participants with DM2)
Number of subjects: 224
Study 24229349 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 224
Study 21324611 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 351
Study 21324611 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 351
Study 21324611 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention disturbance
Number of subjects: 351
Study 21324611 — intervention group
Group type: EXPERIMENTAL
Intervention: Restlessness
Number of subjects: 351
Study 21324611 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal
Number of subjects: 351
Study 19551667 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided customized PRK
Number of subjects: 56
Study 19551667 — intervention group
Group type: COMPARATOR
Intervention: Custom-Q ablation
Number of subjects: 56
Study 16899123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adeno-tonsillectomy
Number of subjects: 406
Study 16899123 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 406
Study 14700552 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 12 months
Number of subjects: 19
Study 14700552 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 19
Study 11299099 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-quantitative food frequency questionnaire (FFQ) administered at baseline (FFQ1) and repeated 1 year later (FFQ2)
Number of subjects: 83
Study 11299099 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-quantitative food frequency questionnaire (FFQ2) compared to 1-week diet records (DRs)
Number of subjects: 83
Study 11299099 — intervention group
Group type: COMPARATOR
Intervention: Diet records (DR) compared to FFQ2
Number of subjects: 83
Study 9402445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment in high compliance group (compliance > or = 75%)
Number of subjects: 0
Study 8291123 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 8291123 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine with Flumazenil
Number of subjects: 0
Study 3625582 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive self-verbalizations (PSV)
Number of subjects: 60
Study 3625582 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative self-verbalizations (NSV)
Number of subjects: 60
Study 3625582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of positive and negative self-verbalizations (PSV + NSV)
Number of subjects: 60
Study 3625582 — intervention group
Group type: COMPARATOR
Intervention: Test-retest control group
Number of subjects: 60
Study 31512157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 40
Study 31512157 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 29478012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Checklist-based interview conducted by healthcare assistant, medication reconciliation, optimisation by general practitioner with decision support system.
Number of subjects: 505
Study 29478012 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): Usual care.
Number of subjects: 505
Study 29478012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Quality of life assessment.
Number of subjects: 505
Study 29478012 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): Quality of life assessment.
Number of subjects: 505
Study 29478012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Functioning assessment.
Number of subjects: 505
Study 29478012 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): Functioning assessment.
Number of subjects: 505
Study 29478012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG): Medication adherence assessment.
Number of subjects: 505
Study 29478012 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): Medication adherence assessment.
Number of subjects: 505
Study 27403743 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly bee venom injections (100 μg)
Number of subjects: 40
Study 27403743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 40
Study 24567394 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intergroup contact with Spanish-speaking confederates inserted into daily routines for a period of days.
Number of subjects: 0
Study 24567394 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study 22444791 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 582
Study 22444791 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 582
Study 20100234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 94
Study 20100234 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 94
Study 17335594 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncatheterized group (n = 28)
Number of subjects: 55
Study 17335594 — intervention group
Group type: COMPARATOR
Intervention: Catheterized group (n = 27)
Number of subjects: 55
Study 15025402 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (adrenaline) for out-of-hospital treatment of anaphylaxis; specific dosage not mentioned, but references to EpiPen Jr 0.15 mg and EpiPen 0.3 mg as available auto-injectors.
Number of subjects: 0
Study 15025402 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine administration methods; subcutaneous injection or inhalation from a pressurized metered-dose inhaler instead of intramuscular injection.
Number of subjects: 0
Study 15025402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose formulations of epinephrine; specific formulations not mentioned.
Number of subjects: 0
Study 11340417 — intervention group
Group type: EXPERIMENTAL
Intervention: eFR (5-min verbal standard instruction in elementary exercises of FR)
Number of subjects: 21
Study 11340417 — intervention group
Group type: EXPERIMENTAL
Intervention: IT (inhalative terbutaline)
Number of subjects: 21
Study 11340417 — intervention group
Group type: COMPARATOR
Intervention: PRT (placebo relaxation technique)
Number of subjects: 21
Study 9100428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 23
Study 9100428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.8 mg/kg
Number of subjects: 23
Study 9100428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9100428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg and 0.8 mg/kg
Number of subjects: 23
Study 7959501 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg magnesium/day in the form of trimagnesium dieitrate
Number of subjects: 43
Study 7959501 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 43
Study 3296735 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 375 mg
Number of subjects: 68
Study 3296735 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 120 mg
Number of subjects: 68
Study 3296735 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (both doses)
Number of subjects: 68
Study 31667542 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model for estimating stone passage rate
Number of subjects: 192
Study 31667542 — intervention group
Group type: COMPARATOR
Intervention: Standard statistical tests
Number of subjects: 192
Study 29141727 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasound (POCUS)
Number of subjects: 425
Study 27514348 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning resource access
Number of subjects: 32
Study 27514348 — intervention group
Group type: COMPARATOR
Intervention: No e-learning resource access (Control)
Number of subjects: 32
Study 24487458 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 200 mcg 10 min prior to tracheal intubation and 6 and 24 h after extubation
Number of subjects: 120
Study 24487458 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 200 mcg 6 and 24 h after extubation
Number of subjects: 120
Study 24487458 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study 23457130 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/Kg of tranexamic acid (TA)
Number of subjects: 70
Study 23457130 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/Kg of tranexamic acid (TA)
Number of subjects: 70
Study 20522472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-measured sachets
Number of subjects: 47
Study 20522472 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighing
Number of subjects: 47
Study 20522472 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoops
Number of subjects: 47
Study 18482376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard sole group
Number of subjects: 40
Study 18482376 — intervention group
Group type: COMPARATOR
Intervention: Soft sole group
Number of subjects: 40
Study 18482376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 15870666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment (2.0 to 0.75 mg/kg per day for 10 days)
Number of subjects: 51
Study 15870666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 15307697 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuanfuling (CFL) sticking
Number of subjects: 90
Study 15307697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmicort inhalation (WM)
Number of subjects: 90
Study 15307697 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 90
Study 11606149 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate, candesartan cilexetil, or both for 17 weeks followed by metoprolol succinate or placebo for 26 weeks
Number of subjects: 768
Study 11606149 — intervention group
Group type: EXPERIMENTAL
Intervention: Study medications (Enalapril maleate, candesartan cilexetil, metoprolol succinate)
Number of subjects: 768
Study 11606149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 9204652 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg daily for 90 days
Number of subjects: 72
Study 9204652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7952252 — intervention group
Group type: EXPERIMENTAL
Intervention: First-voided urine specimens
Number of subjects: 489
Study 7952252 — intervention group
Group type: COMPARATOR
Intervention: Endocervical swab specimens
Number of subjects: 489
Study 7952252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of urine and endocervical swab specimens
Number of subjects: 489
Study 7952252 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for low levels of chlamydial antigen
Number of subjects: 489
Study 3118349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 20
Study 3118349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30466429 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic Experiencing (SE) + Physiotherapy (PT)
Number of subjects: 140
Study 30466429 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT) alone
Number of subjects: 140
Study 28087555 — intervention group
Group type: EXPERIMENTAL
Intervention: Reallocation of prolonged sitting to standing
Number of subjects: 435
Study 28087555 — intervention group
Group type: EXPERIMENTAL
Intervention: Reallocation to stepping
Number of subjects: 435
Study 28087555 — intervention group
Group type: EXPERIMENTAL
Intervention: Reallocation of short sitting time to stepping
Number of subjects: 435
Study 22996027 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill interval training (G(Hill) = 12)
Number of subjects: 32
Study 22996027 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-grade interval training (G(Flat) = 12)
Number of subjects: 32
Study 22996027 — intervention group
Group type: COMPARATOR
Intervention: Control group (G(Con) = 8)
Number of subjects: 32
Study 21107951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (30 mg/ml mixture of oxygen and ozone, 1-7 ml intradiscal and 3 ml periganglionic)
Number of subjects: 270
Study 21107951 — intervention group
Group type: COMPARATOR
Intervention: Physiatric and kinetic treatment (magnetotherapy)
Number of subjects: 270
Study 18272916 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by goserelin
Number of subjects: 1631
Study 18272916 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by tamoxifen
Number of subjects: 1631
Study 18272916 — intervention group
Group type: COMPARATOR
Intervention: Chemo-endocrine therapy
Number of subjects: 1631
Study 18272916 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (tamoxifen alone)
Number of subjects: 1631
Study 16940192 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) intravenous infusion
Number of subjects: 117
Study 16940192 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) ex vivo incubation (1 to 100 micromol/L)
Number of subjects: 117
Study 16940192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 12657408 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT administered soon (<210 sec) after anesthetic induction
Number of subjects: 9
Study 12657408 — intervention group
Group type: COMPARATOR
Intervention: ECT administered later (between 210 sec and 360 sec) after anesthetic induction
Number of subjects: 9
Study 10933121 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (placebo-controlled)
Number of subjects: 18
Study 10933121 — intervention group
Group type: COMPARATOR
Intervention: Efamol (evening primrose oil, rich in gamma-linolenic acid) (placebo-controlled)
Number of subjects: 18
Study 10933121 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (d-amphetamine and Efamol)
Number of subjects: 18
Study 9179214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl-201
Number of subjects: 160
Study 9179214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sestamibi Tc 99m
Number of subjects: 160
Study 1542853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver (CS)
Number of subjects: 90
Study 1542853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 90
Study 1542853 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution (ANH) with CS (ANH-CS)
Number of subjects: 90
Study 1542853 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH with HF (ANH-HF)
Number of subjects: 90
Study 1542853 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Plasmapheresis (APP) with CS (APP-CS)
Number of subjects: 90
Study 1542853 — intervention group
Group type: EXPERIMENTAL
Intervention: APP with HF (APP-HF)
Number of subjects: 90
Study 3924814 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin (amoxycillin 3 g and potassium clavulanate 125 mg)
Number of subjects: 220
Study 3924814 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 3 g with probenecid 1 g by mouth
Number of subjects: 220
Study 30673744 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral care delivery designed to address barriers to HIV care, including decreased clinic visit frequency and flexible, patient-centered care with retention support.
Number of subjects: 1863
Study 30673744 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral care delivery designed to address barriers to HIV care.
Number of subjects: 1863
Study 28533402 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-injected (sick)
Number of subjects: 22
Study 28533402 — intervention group
Group type: COMPARATOR
Intervention: Saline-injected (healthy)
Number of subjects: 22